HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author WLUDARSKI, Sheila Cristina Lordelo FMUSP-HC
LOPES, Lisandro Ferreira
SILVA, Tacio R. Berto e
CARVALHO, Filomena M. FMUSP-HC
WEISS, Lawrence M.
BACCHI, Carlos E. FMUSP-HC
dc.date.issued 2011
dc.identifier.citation APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, v.19, n.2, p.112-118, 2011
dc.identifier.issn 1062-3345
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/23517
dc.description.abstract Breast cancer accounts for approximately one quarter of all cancers in females. HER2 gene amplification or HER2 protein overexpression, detected in about 20% of breast carcinomas, predicts a more aggressive clinical course and determines eligibility for targeted therapy with trastuzumab. HER2 testing has become an essential part of the clinical evaluation of all breast carcinoma patients, and accurate HER2 results are critical in identifying patients who may be benefited from targeted therapy. This study investigated the concordance in the results of HER2 immunohistochemistry assays performed in 500 invasive breast carcinomas between a reference laboratory and 149 local laboratories from all geographic regions of Brazil. Our results showed an overall poor concordance (171 of 500 cases, 34.2%) regarding HER2 results between local and reference laboratories, which may be related to the low-volume load of HER2 assays, inexperience with HER2 scoring system, and/or technical issues related to immunohistochemistry in local laboratories. Standardization of HER2 testing with rigorous quality control measures by local laboratories is highly recommended to avoid erroneous treatment of breast cancer patients.
dc.language.iso eng
dc.publisher LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof Applied Immunohistochemistry & Molecular Morphology
dc.rights restrictedAccess
dc.subject Brazil; HER2; immunohistochemistry; local laboratory; reference laboratory
dc.subject.other her-2/neu gene amplification; rabbit monoclonal-antibody; situ hybridization fish; of-american-pathologists; archival tissue samples; cancer; immunohistochemistry; trastuzumab; oncogene; ihc
dc.title HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil
dc.type article
dc.rights.holder Copyright LIPPINCOTT WILLIAMS & WILKINS
dc.description.group LIM/14
dc.identifier.doi 10.1097/PAI.0b013e3181f0b044
dc.identifier.pmid 20930616
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author WLUDARSKI, Sheila Cristina Lordelo:FM:
hcfmusp.author CARVALHO, Filomena M.:FM:MPT
hcfmusp.author BACCHI, Carlos E.:FM:
hcfmusp.author.external · LOPES, Lisandro Ferreira:Consultoria Patol, BR-18602010 Botucatu, SP, Brazil
· SILVA, Tacio R. Berto e:Consultoria Patol, BR-18602010 Botucatu, SP, Brazil
· WEISS, Lawrence M.:City Hope Natl Med Ctr, Div Pathol, Duarte, CA 91010 USA
hcfmusp.origem.id 2-s2.0-79951942570
hcfmusp.origem.id WOS:000287190000005
hcfmusp.publisher.city PHILADELPHIA
hcfmusp.publisher.country USA
hcfmusp.relation.reference · YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
· Barron JJ, 2009, ONCOLOGIST, V14, P760, DOI 10.1634/theoncologist.2008-0288
· Reddy JC, 2006, CLIN BREAST CANCER, V7, P153, DOI 10.3816/CBC.2006.n.025
· Perez EA, 2006, J CLIN ONCOL, V24, P3032, DOI 10.1200/JCO.2005.03.4744
· Dal Lago L, 2006, MOL CANCER THER, V5, P2572, DOI 10.1158/1535-7163.MCT-06-0129
· Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197
· Dowsett M, 2003, J PATHOL, V199, P418, DOI 10.1002/path.1313
· PRESS MF, 1994, CANCER RES, V54, P2771
· Hilden J, 1996, STAT MED, V15, P969, DOI 10.1002/(SICI)1097-0258(19960530)15:10<969::AID-SIM211>3.0.CO;2-9
· Gancberg D, 2000, AM J CLIN PATHOL, V113, P675
· Perez EA, 2002, MAYO CLIN PROC, V77, P148
· Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1120/JCO.2002.09.094
· Ainsworth R, 2005, J CLIN PATHOL, V58, P1086, DOI 10.1136/jcp.2004.021576
· Roche PC, 2002, J NATL CANCER I, V94, P855
· Rossi E, 2006, APPL IMMUNOHISTO M M, V14, P127, DOI 10.1097/01.pai.0000155795.41654.b1
· Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972
· Fornier M, 2000, SEMIN ONCOL, V27, P38
· Birner P, 2001, CLIN CANCER RES, V7, P1669
· Press MF, 2005, CLIN CANCER RES, V11, P6598, DOI 10.1158/1078-0432.CCR-05-0636
· Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
· van der Vegt B, 2009, MODERN PATHOL, V22, P879, DOI 10.1038/modpathol.2009.37
· Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639
· Powell WC, 2007, APPL IMMUNOHISTO M M, V15, P94, DOI 10.1097/PAI.0b013e31802ced25
· Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
· Ellis IO, 2004, J CLIN PATHOL, V57, P233, DOI 10.1136/jcp.2003.007724
· Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
· Jacobs TW, 1999, J CLIN ONCOL, V17, P1974
· Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396
· Paik S, 2002, J NATL CANCER I, V94, P852
· Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
· Pauletti G, 2000, J CLIN ONCOL, V18, P3651
· Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230
· Bilous M, 2003, MODERN PATHOL, V16, P173, DOI 10.1097/01.MP.0000052102.90815.82
· Fornier M, 2000, SEMIN ONCOL, V27, P92
· GOLDMAN L, 1994, HARRISONS PRINCIPLES, P43
· Gown AM, 2008, MODERN PATHOL, V21, pS8, DOI 10.1038/modpathol.2008.34
· Gown AM, 2008, MODERN PATHOL, V21, p33A
· Hanna W, 2007, Curr Oncol, V14, P149, DOI 10.3747/co.2007.131
· Instituto Nacional de Cancer (Brasil), EST 2010 INC CANC BR
· Kulka J, 2006, PATHOL ONCOL RES, V12, P197
· Leong TYM, 2006, ADV ANAT PATHOL, V13, P263, DOI 10.1097/01.pap.0000213043.16200.92
· O'Malley FP, 2008, ARCH PATHOL LAB MED, V132, P61, DOI 10.1043/1543-2165(2008)132[61:HTIAPS]2.0.CO;2
· Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011
· Papadopoulos S, 2007, CLIN BREAST CANCER, V7, P784, DOI 10.3816/CBC.2007.n.040
· Persons DL, 2006, ARCH PATHOL LAB MED, V130, P325
· Ridolfi RL, 2000, MODERN PATHOL, V13, P866, DOI 10.1038/modpathol.3880154
· Ross JS, 1999, AM J CLIN PATHOL, V112, pS7
· Schnitt SJ, 2001, AM J CLIN PATHOL, V116, P806
· SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
· Tavassoli FA, 2003, WHO CLASSIFICATION T, P13
· Tedesco KL, 2004, J CLIN ONCOL, V22, P1071, DOI 10.1200/JCO.2004.10.046
· Vera-Roman JM, 2004, ARCH PATHOL LAB MED, V128, P627
· Wludarski SCL, 2008, APPL IMMUNOHISTO M M, V16, P466, DOI 10.1097/PAI.0b013e318162625c
· WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22
· Young KD, 1997, ANN EMERG MED, V30, P311, DOI 10.1016/S0196-0644(97)70167-7
· Zarbo RJ, 2003, ARCH PATHOL LAB MED, V127, P549
dc.description.index WoS
hcfmusp.citation.scopus 14
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Estados Unidos
hcfmusp.scopus.lastupdate 2021-08-27


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics